A detailed history of Citigroup Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Citigroup Inc holds 44,577 shares of PHAT stock, worth $222,885. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,577
Previous 31,521 41.42%
Holding current value
$222,885
Previous $569,000 36.56%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

BUY
$7.45 - $18.94 $97,267 - $247,280
13,056 Added 41.42%
44,577 $361,000
Q3 2024

Nov 12, 2024

BUY
$10.25 - $19.5 $232,316 - $441,967
22,665 Added 255.93%
31,521 $569,000
Q2 2024

Aug 12, 2024

BUY
$8.97 - $12.05 $25,214 - $33,872
2,811 Added 46.5%
8,856 $91,000
Q1 2024

May 10, 2024

BUY
$6.21 - $11.05 $2,459 - $4,375
396 Added 7.01%
6,045 $64,000
Q4 2023

Feb 09, 2024

BUY
$6.99 - $10.71 $12,728 - $19,502
1,821 Added 47.57%
5,649 $51,000
Q3 2023

Nov 09, 2023

SELL
$10.26 - $15.7 $53,926 - $82,519
-5,256 Reduced 57.86%
3,828 $39,000
Q2 2023

Aug 10, 2023

BUY
$7.28 - $14.32 $59,244 - $116,536
8,138 Added 860.25%
9,084 $130,000
Q1 2023

May 11, 2023

SELL
$6.19 - $12.36 $1,151 - $2,298
-186 Reduced 16.43%
946 $6,000
Q4 2022

Feb 09, 2023

SELL
$9.18 - $11.53 $1,055 - $1,325
-115 Reduced 9.22%
1,132 $12,000
Q3 2022

Nov 10, 2022

SELL
$6.46 - $12.11 $8,152 - $15,282
-1,262 Reduced 50.3%
1,247 $14,000
Q2 2022

Aug 10, 2022

BUY
$6.2 - $15.5 $2,560 - $6,401
413 Added 19.7%
2,509 $21,000
Q1 2022

May 12, 2022

SELL
$11.55 - $20.06 $61,850 - $107,421
-5,355 Reduced 71.87%
2,096 $29,000
Q4 2021

Feb 10, 2022

BUY
$17.83 - $33.15 $35,142 - $65,338
1,971 Added 35.97%
7,451 $147,000
Q3 2021

Nov 10, 2021

BUY
$30.69 - $36.83 $168,181 - $201,828
5,480 New
5,480 $176,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $196M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.